Efficacy of Ferric Carboxymaltose in Iron Deficiency Anaemia Management in Non Dialysis Dependent Chronic Kidney Disease Patients: A Retrospective Observational Study

Introduction: Iron Deficiency Anaemia (IDA) is prevalent in Non Dialysis Dependent Chronic Kidney Disease (NDD-CKD) patients, necessitating effective treatment strategies. Intravenous Ferric Carboxymaltose (FCM) has emerged as a promising therapy due to its single-dose convenience and potential to improve iron parameters. Aim: To evaluate the efficacy and safety of FCM in correcting IDA and its impact on haematological and renal parameters among NDD-CKD patients. Materials and Methods: A retrospective observational study was conducted in adult outpatients with advanced CKD {estimated Glomerular Filtration Rate (eGFR) ≤30 mL/min/1.73 m²} from Nephrology clinics across multiple centres (6 hospitals) in India from June 2023 to October 2023. Patients received two doses of 500 mg i.v. FCM. Data on haemoglobin, serum ferritin, Transferrin Saturation (TSAT), C-Reactive Protein (CRP), and eGFR were collected at baseline and after FCM administration. Treatment doses were determined based on individual patient parameters and aimed to achieve ferritin ≥500 ng/mL and TSAT ≥30%. Adverse Events (AEs) were monitored throughout the study period. The data were compared using paired t-test. Results: A total of 136 patients (males=77 & females=59) were analysed. Significant improvements were observed in haemoglobin levels (p<0.001), serum ferritin, and TSAT (p<0.001) following FCM treatment. There were no serious AEs reported. Conclusion: Intravenous FCM 500 mg demonstrated efficacy in correcting IDA and improving iron parameters in NDD-CKD patients, with a favourable safety profile. These findings support the use of FCM as a valuable treatment option for managing IDA in this patient population.